PT  - JOURNAL ARTICLE
AU  - Pitzalis, Maristella
AU  - Idda, Maria Laura
AU  - Lodde, Valeria
AU  - Loizedda, Annalisa
AU  - Lobina, Monia
AU  - Zoledzwieska, Magdalena
AU  - Virdis, Francesca
AU  - Delogu, Giuseppe
AU  - Pirinu, Federica
AU  - Marini, Maria Giuseppina
AU  - Mingoia, Maura
AU  - Frau, Jessica
AU  - Lorefice, Lorena
AU  - Fronza, Maria
AU  - Carmagini, Daniele
AU  - Carta, Elisa
AU  - Orrù, Valeria
AU  - Uzzau, Sergio
AU  - Solla, Paolo
AU  - Loi, Federica
AU  - Devoto, Marcella
AU  - Steri, Maristella
AU  - Fiorillo, Edoardo
AU  - Floris, Matteo
AU  - Zarbo, Ignazio Roberto
AU  - Cocco, Eleonora
AU  - Cucca, Francesco
TI  - Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patients
AID  - 10.1101/2021.09.26.21264067
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.26.21264067
4099  - http://medrxiv.org/content/early/2021/09/27/2021.09.26.21264067.short
4100  - http://medrxiv.org/content/early/2021/09/27/2021.09.26.21264067.full
AB  - Objectives Vaccination against COVID-19 is highly recommended to patients affected by multiple sclerosis (MS); however, the impact of MS disease-modifying therapies (DMTs) on the immune response following vaccination has been only partially investigated. Here, we aimed to elucidate the effect of DMTs on the humoral immune response to mRNA-based anti-SARS-CoV-2 vaccines in MS patients.Methods We obtained sera from 912 Sardinian MS patients and 63 healthy controls 30 days after the second dose of BNT162b2 vaccine and tested them for SARS-CoV-2 response using anti-Spike (S) protein-based serology. Previous SARS-CoV-2 infection was assessed by anti-Nucleocapsid (N) serology. Patients were either untreated or undergoing treatment with a total of 13 different DMTs. Differences between treatment groups comprised of at least 10 patients were assessed by generalized linear mixed-effects model. Demographic and clinical data and smoking status were analyzed as additional factors potentially influencing humoral immunity from COVID-19 vaccine.Results MS patients treated with natalizumab, teriflunomide, azathioprine, fingolimod, ocrelizumab, and rituximab showed significantly lower humoral responses compared to untreated patients. We did not observe a statistically significant difference in response between patients treated with the other drugs (dimethyl fumarate, interferon, alemtuzumab and glatiramer acetate) and untreated patients. In addition, older age, male, sex and active smoking were significantly associated with lower antibody titers against SARS-CoV-2. MS patients previously infected with SARS-CoV-2 had significantly higher humoral responses to vaccine than uninfected patients.Conclusion Humoral response to BNT162b2 is significantly influenced by the specific DMTs followed by patients, as well as by other factors such as previous SARS-CoV-2 infection, age, sex, and smoking status. These results are important to inform targeted strategies to prevent clinically relevant COVID-19 in MS patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the Italian Foundation for Multiple Sclerosis - FISM (Grant N. 22021/Special/002).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Review Boards od Sardinia Local Health Agency in Sassari (Sardinia, Italy). Ethical approval was given in 26 January 2021 with the following protocol number:177/20021/EX2492/CE. All enrolled individuals provided written informed consent. Patient data and samples were coded anonymously to ensure confidentiality during sample processing and data analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full list of MS patient and heathy controls that received COVID-19 vaccination with clinical and demographic characteristics is available can be shared upon request.MSMultiple sclerosisDMTsdisease-modifying therapiesSARS-CoV-2severe acute respiratory syndrome coronavirus type-2COVID-19Coronavirus disease 2019AbAntibodySSpikeNNucleocapsid